• 1. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 2. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 3. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 4. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 5. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034

Comprehensive Guide to Hydrazine,(3-methylcyclohexyl)- (CAS No. 741249-15-0): Properties, Applications, and Market Insights

Hydrazine,(3-methylcyclohexyl)- (CAS No. 741249-15-0) is a specialized organic hydrazine derivative gaining attention in pharmaceutical and agrochemical research. This compound, characterized by its 3-methylcyclohexyl substituent, exhibits unique reactivity patterns that make it valuable for heterocyclic synthesis and intermediate production. As researchers increasingly explore nitrogen-containing compounds for drug discovery, the demand for tailored hydrazine derivatives like this has grown significantly.

The molecular structure of Hydrazine,(3-methylcyclohexyl)- features a cyclohexane ring with a methyl group at the 3-position, connected to a hydrazine functional group. This configuration provides both steric hindrance and electronic effects that influence its chemical behavior. Recent studies highlight its potential as a building block for pharmaceutical intermediates, particularly in the development of central nervous system (CNS) targeting compounds. The compound's lipophilicity, influenced by the methylcyclohexyl moiety, makes it particularly interesting for blood-brain barrier penetration studies.

In synthetic applications, Hydrazine,(3-methylcyclohexyl)- demonstrates excellent reactivity in condensation reactions and cyclization processes. Its nucleophilic character at the nitrogen atoms allows for diverse transformations, making it valuable for creating nitrogen-rich heterocycles. The compound's stability under various pH conditions has been noted in recent process chemistry studies, suggesting advantages for scale-up production in industrial settings.

The pharmaceutical industry shows growing interest in 741249-15-0 as a potential precursor for neurologically active compounds. With the global focus on neurodegenerative disease treatments and psychiatric medications, researchers are investigating how the 3-methylcyclohexyl hydrazine structure might contribute to novel drug scaffolds. Some preliminary studies suggest possible applications in Parkinson's disease research, though extensive clinical validation remains ongoing.

From a green chemistry perspective, recent developments have explored more sustainable synthesis routes for Hydrazine,(3-methylcyclohexyl)-. Innovations in catalytic processes and solvent-free conditions aim to reduce the environmental impact of producing such specialty chemicals. These advancements align with the pharmaceutical industry's push toward sustainable manufacturing practices and green synthetic methodologies.

The global market for functionalized hydrazines like 741249-15-0 has shown steady growth, driven by increasing R&D investment in targeted therapies. Market analysts note particular demand from contract research organizations (CROs) and custom synthesis providers serving the pharmaceutical sector. The compound's relative novelty means it currently occupies a specialty chemicals niche, with limited but growing commercial availability.

Quality control standards for Hydrazine,(3-methylcyclohexyl)- typically emphasize HPLC purity verification and structural confirmation through NMR spectroscopy. Storage recommendations generally suggest inert atmosphere conditions and protection from moisture absorption to maintain stability. These handling protocols reflect the compound's sensitivity to oxidative degradation, a common characteristic of many hydrazine-based compounds.

Future research directions for CAS 741249-15-0 may explore its potential in asymmetric synthesis applications or as a component in metal-organic frameworks (MOFs). The compound's structural features suggest possible utility in developing chiral catalysts or molecular recognition systems. As computational chemistry methods advance, in silico studies of this compound's interactions with biological targets may reveal additional therapeutic possibilities.

For researchers considering 3-methylcyclohexyl hydrazine in their work, recent literature reviews suggest starting with small-scale reactivity screening to establish optimal conditions. The compound's steric profile may influence reaction outcomes differently than simpler alkyl hydrazines, requiring adjusted stoichiometric ratios in some transformations. Several published protocols now exist for its incorporation into pyrazole and triazole ring systems.

In analytical applications, Hydrazine,(3-methylcyclohexyl)- has shown promise as a derivatization agent for certain carbonyl compounds. Its bulky substituent can improve chromatographic separation of reaction mixtures in some cases. These characteristics make it potentially valuable for analytical method development in complex organic synthesis monitoring.

The intellectual property landscape surrounding 741249-15-0 includes several patents describing its use in medicinal chemistry applications. Most focus on its incorporation into biologically active molecules rather than claims on the compound itself. This suggests opportunities for novel applications while respecting existing patent boundaries in pharmaceutical development.

From a regulatory standpoint, Hydrazine,(3-methylcyclohexyl)- currently falls under general laboratory chemical classifications in most jurisdictions. However, researchers should monitor evolving chemical regulations, particularly concerning hydrazine derivatives, as testing requirements may change with increased usage. Proper risk assessment protocols should accompany any experimental work with this compound.

Supply chain considerations for CAS 741249-15-0 highlight its status as a low-volume specialty chemical. Most providers offer gram-to-kilogram quantities with typical lead times of 4-8 weeks for synthesis and purification. The compound's custom synthesis nature means pricing remains significantly higher than bulk commodity chemicals, reflecting its research-grade purity requirements.

In conclusion, Hydrazine,(3-methylcyclohexyl)- represents an interesting case study in how tailored hydrazine derivatives can enable novel chemical space exploration for pharmaceutical applications. Its combination of steric effects and nitrogen reactivity offers synthetic chemists a valuable tool for constructing complex nitrogen heterocycles. As research into CNS-targeting compounds continues to expand, this compound's role in medicinal chemistry may grow accordingly, making it a chemical worth watching in coming years.

• 158438-47-2(Hydrazine,(4-methylcyclohexyl)-)
• 45659-67-4(2-METHYLCYCLOHEXYL-HYDRAZINE)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)